Greendale GA, Judd HL: The menopause: Health implications and clinical management. Prog Geriat 41:426–436, 1993.
McKinley SM, Brambilla PJ, Posner JG: The normal menopause transition. Maturitas 14:103–115, 1992.
Scotti RJ, Ostergard DR: The urethral syndrome. Clin Obstet Gynecol 27:525–529, 1984.
Notelovitz M: Gynecologic problems of menopausal women. Changes in genital tissues. Geriatrics 33:24–30, 1978.
Richelson LS, Wahner HW, Melton LJ III, Riggs BL: Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 311:1273–1275, 1984.
Aitken JM, Hart DM, Anderson JG, Lindsay R, Smith DA, Speirs CF: Osteoporosis after oophorectomy for nonmalignant disease in premenopausal women. Br Med J 2:325–328, 1973.
Wasserman SHS, Barzel VS: Involution osteoporosis. N Engl J Med 314:1676–1686, 1986.
Wasserman SHS, Barzel VS: Osteoporosis, the state-of-art in 1987: A review. Semin Nucl Med 17:283–292, 1987.
National Conference on Women's Health Series: Osteoporosis [special conference]. Bethesda MD, October 30, 1987.
Wenger NK, Speroff L, Packard B: Cardiovascular health in women. N Engl J Med 329:247–256, 1993.
Gordon T, Kannel WB, Hjortland MC, McNamara PM: Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 89:157–161, 1978.
Rosenberg L, Hennekens CHE, Rosner B, Belanger C, Rothman KJ, Speiger FE: Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 139:47–51, 1981.
Mathews KA, Meihlahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR: Menopause and risk factors for coronary heart disease. N Engl J Med 321:641–646, 1989.
Heart and Strokes — Facts. Am Heart Assoc, Dallas, 1992.
Steingold KA, Langer L, Chetkowski RJ, de Fazio JD, Matt DW, Meldrum DR, Judd HJ: Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 61:627–632, 1985.
Sonnedecker EUW, Polakow ES: Effects of conjugated equine estrogen with and without the addition of cyclical medrogestone on hot flashes, liver function, blood pressure and endocrinological indices. S Afr Med J 77:281–285, 1990.
Clayden JR, Bell JW, Pollard P: Menopausal flushing: Double blind trial of a non-hormonal medication. Br Med J 1:409–412, 1974.
Tulandi T, Samarthji L: Menopausal hot flush. Obstet Gynecol Surv 40:553–563, 1985.
Henderson BE, Paganini-Hill A, Ross RK: Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 159:312–317, 1988.
Stamper MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FR, Hennekens CH: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurse's Health Study. N Engl J Med 325:745–762, 1991.
Lobo RA: Clinical review 27 — effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 73: 925–930, 1991.
Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM: Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 54:74–79, 1979.
Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 328: 1069–1075, 1993.
Grundy SM: Cholesterol and coronary heart disease: A new era. JAMA 256:249–2858, 1986.
Atherosclerosis Study Group: Optimal resources for primary prevention of diseases. Circulation 70:157A-205A, 1984.
Wren BG: The effect of estrogen on the female cardiovascular system. Med J Austr 157:202–208, 1992.
Bush TL, Barrett-Connor E: Estrogen use in cardiovascular disease. Epidemiol Rev 7:80–104, 1985.
Stampfer MJ: Postmenopausal estrogen use in heart disease. N Engl J Med 316:164–165, 1987.
Adams MR, Clarkson TB, Koritnik DR, Nash HA: Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques. Fertil Steril 47:1010–1018, 1987.
Williams JK, Adams MR, Klopfentein HS: Estrogen modulates responses of atherotic coronary arteries. Circulation 81:1680–1687, 1990.
Richelson LS, Wahner HW, Melton LJ, Riggs BL: Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 311: 1273–1275, 1984.
Stevenson JC: Pathogenesis, prevention and treatment of osteoporosis. Obstet Gynecol 75:365–368, 1990.
Nordin BEC, Need AG, Bridges A, Horowitz M: Relative contributions of years since menopause, age and weight to vertebral density in postmenopausal women. J Clin Endocrinol Metab 74:20–23, 1992.
Slemenda CW, Christian JC, Williams CJ, Norton JA, Johnston CC: Genetic determinants of bone mass in adult women: A reevaluation of the twin model and the potential importance of gene interaction on heritability estimates. J Bone Min Res 6:561–567, 1991.
Ettinger B, Genant HK, Cann CE: Long term estrogen replacement therapy prevents bone loss and fractures. Ann Int Med 102:319–324, 1985.
Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RLT, Riggs BL: Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Int Med 117:1–9, 1992.
Mitlak BH, Nussbaum SR: Diagnosis and treatment of osteoporosis. Annu Rev Med 44:265–277, 1993.
Consensus Conference: Osteoporosis. JAMA 252:799–802, 1984.
Barrett-Connor E: Postmenopausal estrogen, cancer and other considerations. Womens Health 11:179–195, 1986.
Ettinger B, Genant HK, Cann CE: Postmenopausal bone loss is prevented by treatment with low dosage estrogen with calcium. Ann Intern Med 106:40–45, 1987.
Lindsay R, Hart DM, Forrest C, Barid C: Prevention of spinal osteoporosis in oophorectomized women. Lancet ii:1151–1154, 1989.
Weiss NS, Ure CL, Ballard JH, et al: Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogens. N Engl J Med 303:1195–1198, 1980.
Johnson RE, Specht EE: The role of hip fracture in postmenopausal females with or without estrogen drug exposure. Am J Public Health 71:138–144, 1981.
Naessen T, Persson I, Adami HO, Bergstrom R, Bergkvist L: Hormone replacement therapy and the risk for first hip fracture: A prospective, population- based cohort study. Ann Int Med 113:95–103, 1990.
Riggs BL, Melton LJ: The prevention and treatment of osteoporosis. N Engl J Med 327:620–627, 1992.
Peck WA, Riggs BL, Bell NH, Wallace RB, Johnston CC, Gordon SL, Shuleman LE: Research directions in osteoporosis. Am J Med 84:275–282, 1988.
Cavanaugh DJ, Cann CE: Brisk walking does not stop bone loss in postmenopausal women. Bone 9:201–204, 1988.
Riggs BL, Hodgson SF, O'Fallon EYS, et al: Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802–809, 1990.
Fatourechi V, Heath H: Salmon calcitonin in the treatment of postmenopausal osteoporosis. Ann Int Med 107:923–925, 1987.
Heaney RP, Baylink DJ, Johnston CC, Melton LJ, Meunier PJ, Murray TM, Nagant de Deuxchaisnes C: Fluoride therapy for the vertebral crush fracture syndrome. Ann Int Med 111:678–680, 1989.
Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S: A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 323:878–883, 1990.
Ott SM, Chesnut CH: Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Int Med 110:267–274, 1989.
Tilyard NW, Spears GFS, Conn B, Thomson J, Dovey S: Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357–362, 1991.
Hodsman AB, Drost DJ: The response of vertebral bone mineral density during the treatment of osteoporosis with sodium fluoride. J Clin Endocrinol Metab 69:932–938, 1989.
Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Janover MJ, Mysiw WJ, Kohse L, Rao B, Steiger P, Richmond B, Chesnut CH III: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73–9, 1990.
Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322: 1265–1271, 1990.
Anon: Etidronate for postmenopausal osteoporosis. Med Lett 32:111–112, 1990.
Dupont WD, Page DL: Breast cancer risk associated with proliferative disease, age at first birth and a family history of breast cancer. Am J Epidemiol 125:769–779, 1987.
Henderson CI: Risk factors for breast cancer development. Cancer 71:2127–2140, 1993.
Colditz GA, Willett WC, Hunter DJ, Stampfer MJ, Manson JE, Hennekens CH, Rosner BA, Speizer FE: Family history, age and risk of breast cancer: Prospective data from the nurse's health study. JAMA 270:338–343, 1993.
Rosenberg L, Miller DR, Kaufman DW, Helmrich SP, Stolley PD, Schottenfeld D, Shapiro S: Breast cancer and oral contraceptive use. Am J Epidemiol 119:167–176, 1984.
The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute for Child Health and Human Development: Oral contraceptives and the risk of breast cancer. N Engl J Med 315:405–411, 1986.
Kay CR, Hannaford PC: Breast cancer and the pill — a further report from the Royal College of General Practitoners' oral contraception study. Br J Cancer 58:675–680, 1988.
UK National Case Control Study Group: Oral contraceptive use and breast cancer risk in young women. Lancet i:973–982, 1989.
Romieu I, Berlin JA, Colditz G: Oral contraceptives and breast cancer: Review and meta-analysis. Cancer 66:2253–2263, 1990.
Thomas DB, Noonan EA, and the WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Risk of breast cancer in relation to use of combined oral contraceptives near the age of menopause. Cancer Causes and Control 2:389–394, 1991.
Gamrell RD: Estrogen-progestogen replacement and cancer risk. Hosp Pract 90(March):81–99, 1990.
Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S: Breast cancer risk after estrogen replacement therapy: Results from the Toronto Breast Cancer Study. Am J Epidemiol 134:1386–1395, 1991.
Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG, Shapiro S: Estrogen replacement therapy and the risk of breast cancer: Results from the case-control surveillance study. Am J Epidemiol 134:1375–1385, 1991.
Heinrich JB: The postmenopausal estrogen/breast cancer controversy. J Am Med Assoc 268:1900–1902, 1992.
Hoover R, Glass A, Finkle WD, Azevedo D, Milne K: Conjugated estrogens and breast cancer risk in women. JNCI 67:815–820, 1981.
Brinton LA, Hoover RN, Szklo M, Fraumeni JF: Menopausal estrogen use and risk of breast cancer. Cancer 47:2517–2522, 1981.
Hulka BS, Chambless LE, Deubner DC, Wilkinson WE: Breast cancer and estrogen replacement therapy. Am J Obstet Gynecol 143:638–644, 1982.
Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C: The risk of breast cancer after estrogen and estrogen-progesterone replacement. N Engl J Med 321:293–297, 1989.
Gambrell RD, Maier RC, Sanders BI: Decreased incidence of breast cancer in postmenopausal estrogen-progesterone users. Obstet Gynecol 62:435–443, 1983.
Brinton LA, Hoover R, Fraumeni JF: Menopausal oestrogens and breast cancer risk: An expanded casecontrol study. Br J Cancer 54:825–832, 1986.
Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW: The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 257:209–215, 1987.
Buring JE, Hennekens CH, Lipnick RJ, Willett W, Stampfer MJ, Rosner B, Peto R, Speizer FR: A prospective cohort study of postmenopausal hormone use and risk of breast cancer in US women. Am J Epidemiol 125:939–947, 1987.
Ewertz M: Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 42:832–838, 1988.
Key TJA, Pike MC: The role of oestrogens and progestogens in the epidemiology and prevention of breast cancer. J Cancer Clin Oncol 24:29–43, 1988.
Colditz GA, Stampfer MJ, Willett WC, Hennekens CH, Rosner B, Speizer FE: Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 264:2648–2653, 1990.
Harris RE, Namboodiri KK, Wynder EL: Breast cancer risk: Effects of estrogen replacement therapy and body mass. J Natl Cancer Inst 84:1576–1582, 1992.
Whitcroft SIJ, Stevenson JC: Hormone replacement therapy: risks and benefits. Clin Endocrinol 36:15–20, 1992.
Barrett-Connor E: Risks and benefits of replacement estrogen. Annu Rev Med 43:239–251, 1992.
Clinical Guideline: Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Int Med 117:1038–1041, 1992.
Chamberlain G: Hormone replacement therapy and breast cancer. Br J Obstet Gynaecol 100:404–407, 1993.
Dupont WD, Page DL: Menopausal estrogen replacement therapy and breast cancer. Arch Int Med 151:67–72, 1991.
Armstrong BK: Oestrogen therapy after the menopause — boon or bane? Med J Austral 148:213–214, 1988.
Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders D, Berkelman RL: A metaanalysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265:1985–1990, 1991.
Silero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R: Menopausal hormone replacement therapy and breast cancer: A meta-analysis. Obstet Gynecol 79:286–294, 1992.
Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 117:1016–1037, 1992.
Colditz GA, Egan KM, Stampfer MJ: Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies. Am J Obstet Gynecol 168:1473–80, 1993.
Ross RK, Paganini-Hill A, Gerkins VR, Mack TM, Pfeffer P, Arthur M, Henderson BE: A case-control study of menopausal estrogen therapy and breast cancer. JAMA 243:1635–1639, 1980.
Kauffman DW, Miller DR, Rosenberg L, Helmrich SP, Stolley P, Schottenfeld D, et al: Noncontraceptive estrogen use and the risk of breast cancer. JAMA 252:63–67, 1984.
McDonald JA, Weiss NS, Dalling JR, Francis AM, Polissar L: Menopausal estrogen use and the risk of breast cancer. Breast Cancer Res Treat 7:193–199, 1986.
La Vecchia C, De Carli A, Parazihni F, Gentile A, Liberati C, Franceschi S: Noncontraceptive oestrogens and the risk of breast cancer in women. Int J Cancer 38:853–858, 1986.
Byrd BF, Burch JC, Vaughn WK: The impact of long-term estrogen support after hysterectomy: a report of 1016 cases. Ann Surg 185:574–580, 1977.
Hunt K, Vessey M, McPherson K: Mortality in a cohort of long-term users of hormone replacement therapy: Our updated analysis. Br J Obstet Gynaecol 97:1080–1086, 1990.
Bergkvist L, Adami H, Persson I, et al: Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 130:221–228, 1989.
Patel HZ, Buzdar AU, Hortobagyi GN: Role of adjuvant chemotherapy in male breast cancer. Cancer 64:1583–1585, 1989.
Cutuli BF, Velten M, Florentz P, Hedelin G, Horiot JC, Pavy JJ, Nguyen TD, Fachini T, Lesaunier F, Prevot G, Keiling R, Poulin G, Sztermer JF, Crestin M, Monnier A, Jung GM: Cancer du sein chez l'homme: 106 observations. La Presse Medicale 22:463–466, 1993.
Stoll BA, Parbhoo S: Treatment of menopausal symptoms in breast cancer patients. Lancet i:1278–1279, 1988.
Wile AG, DiSaia PJ: Hormones and breast cancer. Am J Surg 157:438–442, 1989.
Creasman WT: Estrogen replacement therapy: Is previously treated cancer a contraindication? Obstet Gynecol 77:309–312, 1991.
Theriault RL, Vassilopoulou-Sellin R: A clinical dilemma: Estrogen replacement therapy in postmenopausal women with a background of primary breast cancer. Ann Oncol 2:709–717, 1991.
Eden JA: Oestrogen and the breast. 2. The management of the menopausal woman with breast cancer. Med J Austral 157:247–250, 1992.
Lobo RA: Hormone replacement therapy. Oestrogen replacement after treatment for breast cancer? Lancet 341:1313–1314, 1993.
Marchant DJ: Estrogen-replacement therapy after breast cancer. Risk versus benefits. Cancer 71:2169–2176, 1993.
Powles TJ, Hickish T, Casey S, O'Brien M: Hormone replacement after breast cancer. Lancet 342:60–61, 1993.
Sutton R, Buzdar AU, Hortobagyi GN: Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 65:847–850, 1990.
Cooper DR, Butterfield J: Pregnancy subsequent to mastectomy for cancer of the breast. Ann Surg 171:429–433, 1970.
Danforth DN: How subsequent pregnancy affects outcome in women with a prior breast cancer. Oncology 5:23–35, 1991.
Stoll BA: Hormone replacement therapy in women treated for breast cancer. J Cancer Clin Oncol 25:1909–1913, 1989.
Wile AG, Opfell RW, Margileth DA: Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 165:372–375, 1993.
Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL: Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 67:326–330, 1986.
Kadri AZ: Hormone replacement therapy — a survey of premenopausal women in a community setting. Br J Gen Pract 41:109–112, 1991.
Schmitt N, Gogate J, Rothert M, et al: Capturing and clustering women's judgment policies: The case of hormonal therapy for menopause. J Gerontol Psych Sci 46:92–101, 1991.
Ferguson KJ, Hoegh C, Johnson S: Estrogen replacement therapy: A survey of women's knowledge and attitudes. Arch Int Med 149:133–136, 1989.
Vassilopoulou-Sellin R, Zolinski C: Estrogen replacement therapy in women with breast cancer: A survey of patient attitudes. Am J Med Sci 304:145–149, 1992.
Cancer Surveillance Epidemiology and End Results Reporting System, Bethesda MD: Dept Health Educ Welfare, Natl Inst Health, 1992.
Kelsey JL, Gammon MD: Epidemiology of breast cancer. Epidemiol Revs 12:228–240, 1990.
Cancer Statistics 1991. Ca - A Cancer Journal for Clinicians 41:19–36, 1991.
Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T: The lifetime risk of developing breast cancer. JNCI 85:892–849, 1993.